Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 1, 2011, Pages 109-116

  Lin, T C ^a   Yang, C Y ^a   Kao Yang, Y H ^a   Lin, S J ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HYPNOTIC AGENT; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; FEMALE; FRACTURE; HAZARD RATIO; HEALTH INSURANCE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; STEROID THERAPY; TAIWAN; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; ALENDRONATE; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COMORBIDITY; DATA MINING; DATABASES, FACTUAL; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; SPINAL FRACTURES; TAIWAN;

EID: 79959378065     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.62     Document Type: Article

References (30)

1. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation, Washington, DC, 2010).
2. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation (National Osteoporosis Foundation, Washington, DC, 2002).
3. Burge, R., Dawson-Hughes, B., Solomon, D.H., Wong, J.B., King, A. & Tosteson, A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22, 465-475 (2007). (Pubitemid 46797130)
4. Klotzbuecher, C.M., Ross, P.D., Landsman, P.B., Abbott, T.A. 3rd & Berger, M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J. Bone Miner. Res. 15, 721-739 (2000). (Pubitemid 30174026)
5. Kanis, J.A. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399-428 (2008).
6. Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr, Forciea, M.A. & Owens, D.K. Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 149, 404-415 (2008).
7. Black, D.M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535-1541 (1996). (Pubitemid 26411651)
8. Harris, S.T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282, 1344-1352 (1999). (Pubitemid 29483192)
9. McClung, M.R. et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344, 333-340 (2001). (Pubitemid 32107641)
10. Black, D.M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007). (Pubitemid 46698462)
11. Kothawala, P., Badamgarav, E., Ryu, S., Miller, R.M. & Halbert, R.J. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc. 82, 1493-1501 (2007). (Pubitemid 350211697)
12. Solomon, D.H. et al. Compliance with osteoporosis medications. Arch. Intern. Med. 165, 2414-2419 (2005). (Pubitemid 41640855)
13. Cramer, J.A., Gold, D.T., Silverman, S.L. & Lewiecki, E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos. Int. 18, 1023-1031 (2007). (Pubitemid 47019996)
14. Blouin, J., Dragomir, A., Moride, Y., Ste-Marie, L.G., Fernandes, J.C. & Perreault, S. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br. J. Clin. Pharmacol. 66, 117-127 (2008). (Pubitemid 351822168)
15. Cotte, F.E., Mercier, F. & De Pouvourville, G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin. Ther. 30, 2410-2422 (2008).
16. Gallagher, A.M., Rietbrock, S., Olson, M. & van Staa, T.P. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J. Bone Miner. Res. 23, 1569-1575 (2008).
17. Siris, E.S. et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81, 1013-1022 (2006). (Pubitemid 44175011)
18. Rabenda, V. et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 19, 811-818 (2008).
19. McCombs, J.S., Thiebaud, P., McLaughlin-Miley, C. & Shi, J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-287 (2004). (Pubitemid 38781153)
20. Caro, J.J., Ishak, K.J., Huybrechts, K.F., Raggio, G. & Naujoks, C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15, 1003-1008 (2004). (Pubitemid 40064656)
21. Brankin, E., Walker, M., Lynch, N., Aspray, T., Lis, Y. & Cowell, W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr. Med. Res. Opin. 22, 1249-1256 (2006). (Pubitemid 44085576)
22. Huybrechts, K.F., Ishak, K.J. & Caro, J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-928 (2006). (Pubitemid 44498580)
23. Cadarette, S.M., Katz, J.N., Brookhart, M.A., Sturmer, T., Stedman, M.R. & Solomon, D.H. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann. Intern. Med. 148, 637-646 (2008). (Pubitemid 351669108)
24. Morin, S., Rahme, E., Behlouli, H., Tenenhouse, A., Goltzman, D. & Pilote, L. Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos. Int. 18, 1625-1632 (2007). (Pubitemid 47620316)
25. Pinheiro, M.M., Ciconelli, R.M., Martini, L.A. & Ferraz, M.B. Clinical risk factors for osteoporotic fractures in Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Osteoporos. Int. 20, 399-408 (2009).
26. Chang, C.M., Wu, E.C., Chang, I.S. & Lin, K.M. Benzodiazepine and risk of hip fractures in older people: a nested case-control study in Taiwan. Am. J. Geriatr. Psychiatry 16, 686-692 (2008).
27. Wagner, A.K. et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch. Intern. Med. 164, 1567-1572 (2004). (Pubitemid 38970480)
28. Takkouche, B., Montes-Martinez, A., Gill, S.S. & Etminan, M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 30, 171-184 (2007). (Pubitemid 46193066)
29. Weycker, D., Macarios, D., Edelsberg, J. & Oster, G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos. Int. 18, 271-277 (2007). (Pubitemid 46233172)
30. Curtis, J.R., Westfall, A.O., Cheng, H., Lyles, K., Saag, K.G. & Delzell, E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J. Bone Miner. Res. 23, 1435-1441 (2008).